NIKA · Nika Pharmaceuticals, Inc · Insider Trading
$0.41
At close · Sep 7
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 10, 2026
Market Cap
$431.19M
Shares
1.05B
Volume · Sep 7
2500
Avg daily vol (10 sessions)
1247
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-03-18 | Savov Dimitar Slavchev |
Director, CEO, CFO, President, 10% Owner |
Sell↓
|
Common Stock
|
2,000,000 |
| 2023-06-02 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Sell↓
|
Common
|
3,500,000 |
| 2023-01-31 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Sell↓
|
Common
|
1,500,000 |
| 2023-01-10 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Sell↓
|
Common
|
6,300,000 |
| 2022-10-24 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Sell↓
|
Common
|
3,000,000 |
| 2022-09-26 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Sell↓
|
Common
|
1,250,000 |
| 2022-09-12 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Sell↓
|
Common
|
7,000,000 |
| 2022-07-20 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Other↑
Filing footnotes — Common (Indirect)
30-1 Forward Split as dividend |
Common
(I)
|
145,000,000 |
| 2022-07-20 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Other↑
Filing footnotes — Common (Direct)
30-1 forward split as dividend |
Common
|
333,181,000 |
| 2022-04-29 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Other↑
Filing footnotes — Common (Indirect)
Intermediation Agreement valued at $50,000 |
Common
(I)
|
5,000,000 |
| 2022-04-13 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Other↑
Filing footnotes — Preferred A Stock (Direct)
Issuance per terms of Exclusive Rights Agreement Exclusive rights valued at 3,000,000 |
Preferred A Stock
|
10,000,000 |
| 2022-04-13 | NIKA PHARMACEUTICALS, INC |
Director, Secretary, 10% Owner |
Buy↑
|
Common
|
11,489,000 |
Legend
Buy — open-market purchase
Sell — open-market sale
↑ Shares acquired
↓ Shares disposed (gift, conversion, tax…)
Showing 1–12 of 12 transactions